Year: 2017
Type: article
Abstract: Brand-name drug companies have been filing citizen petitions with the Food and Drug Administration expressing concerns about generic drugs under review, in last-ditch efforts to hold off competition. A promising solution lies in erecting procedural blocks.
Source: New England Journal of Medicine
DOI: 10.1056/nejmp1700202
Authors: Robin Feldman, Connie Wang
Institution: University of California Hastings College of the Law
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W2592033398